Diversified Trust Co Sells 1,038 Shares of West Pharmaceutical Services, Inc. (NYSE:WST)

Diversified Trust Co reduced its position in shares of West Pharmaceutical Services, Inc. (NYSE:WSTFree Report) by 55.7% in the first quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 827 shares of the medical instruments supplier’s stock after selling 1,038 shares during the quarter. Diversified Trust Co’s holdings in West Pharmaceutical Services were worth $327,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of WST. AQR Capital Management LLC grew its stake in shares of West Pharmaceutical Services by 3.9% in the third quarter. AQR Capital Management LLC now owns 53,060 shares of the medical instruments supplier’s stock worth $19,909,000 after acquiring an additional 2,002 shares during the period. Glenmede Trust Co. NA grew its stake in shares of West Pharmaceutical Services by 12.4% in the third quarter. Glenmede Trust Co. NA now owns 3,575 shares of the medical instruments supplier’s stock worth $1,341,000 after acquiring an additional 394 shares during the period. Advisors Asset Management Inc. grew its stake in shares of West Pharmaceutical Services by 3.0% in the third quarter. Advisors Asset Management Inc. now owns 6,346 shares of the medical instruments supplier’s stock worth $2,381,000 after acquiring an additional 186 shares during the period. Lido Advisors LLC grew its stake in shares of West Pharmaceutical Services by 15.5% in the third quarter. Lido Advisors LLC now owns 788 shares of the medical instruments supplier’s stock worth $296,000 after acquiring an additional 106 shares during the period. Finally, Seven Eight Capital LP bought a new stake in shares of West Pharmaceutical Services in the third quarter worth approximately $497,000. 93.90% of the stock is currently owned by institutional investors.

West Pharmaceutical Services Stock Performance

Shares of WST stock opened at $320.90 on Friday. The company has a 50 day moving average price of $338.20 and a 200-day moving average price of $359.56. West Pharmaceutical Services, Inc. has a 52 week low of $310.00 and a 52 week high of $415.73. The firm has a market capitalization of $23.37 billion, a PE ratio of 42.34, a P/E/G ratio of 5.70 and a beta of 1.00. The company has a quick ratio of 1.95, a current ratio of 2.61 and a debt-to-equity ratio of 0.03.

West Pharmaceutical Services (NYSE:WSTGet Free Report) last announced its earnings results on Thursday, April 25th. The medical instruments supplier reported $1.56 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.29 by $0.27. The company had revenue of $695.40 million during the quarter, compared to analyst estimates of $670.62 million. West Pharmaceutical Services had a net margin of 19.42% and a return on equity of 20.57%. The firm’s quarterly revenue was down 3.0% compared to the same quarter last year. During the same period in the previous year, the business posted $1.98 earnings per share. As a group, equities research analysts expect that West Pharmaceutical Services, Inc. will post 7.76 earnings per share for the current year.

West Pharmaceutical Services Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, August 7th. Investors of record on Wednesday, July 31st will be given a dividend of $0.20 per share. The ex-dividend date is Wednesday, July 31st. This represents a $0.80 annualized dividend and a yield of 0.25%. West Pharmaceutical Services’s dividend payout ratio (DPR) is 10.55%.

Insider Activity at West Pharmaceutical Services

In related news, CEO Eric Mark Green sold 66,000 shares of the business’s stock in a transaction that occurred on Tuesday, May 7th. The shares were sold at an average price of $366.65, for a total transaction of $24,198,900.00. Following the completion of the sale, the chief executive officer now directly owns 152,908 shares in the company, valued at $56,063,718.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other West Pharmaceutical Services news, CEO Eric Mark Green sold 66,000 shares of West Pharmaceutical Services stock in a transaction that occurred on Tuesday, May 7th. The shares were sold at an average price of $366.65, for a total transaction of $24,198,900.00. Following the transaction, the chief executive officer now owns 152,908 shares of the company’s stock, valued at $56,063,718.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Silji Abraham sold 1,800 shares of West Pharmaceutical Services stock in a transaction that occurred on Wednesday, June 12th. The shares were sold at an average price of $330.78, for a total transaction of $595,404.00. Following the transaction, the senior vice president now directly owns 2,860 shares in the company, valued at approximately $946,030.80. The disclosure for this sale can be found here. 0.53% of the stock is currently owned by company insiders.

West Pharmaceutical Services Profile

(Free Report)

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.

Featured Stories

Institutional Ownership by Quarter for West Pharmaceutical Services (NYSE:WST)

Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.